We have a number of things that we focus on on cancer outcomes, including implementing a lung cancer pathway through the lens of value-based healthcare. One-year survival from lung cancer has improved 5.8 percentage points, and five-year survival by 4 percentage points, between 2005 and 2009 and between 2010 and 2014. The cancer patient experience survey showed that 93 per cent of lung cancer patients reported a positive experience of their care—a significant improvement when compared against the previous survey.

We do have a national leadership group of expert clinicians, the Wales thoracic oncology group, that works within the cancer network to co-ordinate activity in Wales. The group has overseen a national lung cancer initiative over the past three years that included a symptom awareness campaign, a programme to get people ready for surgery, and to improve access to that surgery. We've also improved access to stereotactic ablative radiotherapy by funding new equipment at the Velindre Cancer Centre so that patients can access the advanced radiotherapy technique in Wales. In addition, the new treatment fund has led to faster access to a number of new drugs, including several for lung cancer. So, the Member can be assured that it is a matter we are keeping under close regard.